These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 35836202

  • 1. Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment.
    Feng WH, Chen YY, Kuo YS, Lin KH, Tsai YM, Wu TH, Huang HK, Huang TW.
    BMC Cancer; 2022 Jul 14; 22(1):768. PubMed ID: 35836202
    [Abstract] [Full Text] [Related]

  • 2. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Xu X, Sun ZY, Wu HW, Zhang CP, Hu B, Rong L, Chen HY, Xie HY, Wang YM, Lin HP, Bai YR, Ye Q, Ma XM.
    Radiat Oncol; 2021 Jul 19; 16(1):132. PubMed ID: 34281566
    [Abstract] [Full Text] [Related]

  • 3. Role of 18F-FDG-PET/CT in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Sasaki K, Uchikado Y, Okumura H, Omoto I, Kita Y, Arigami T, Uenosono Y, Owaki T, Maemura K, Natsugoe S.
    Anticancer Res; 2017 Feb 19; 37(2):859-864. PubMed ID: 28179343
    [Abstract] [Full Text] [Related]

  • 4. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Furukawa T, Yamakita I, Kurokawa T, Okada M.
    Ann Thorac Surg; 2016 Oct 19; 102(4):1132-9. PubMed ID: 27319990
    [Abstract] [Full Text] [Related]

  • 5. Maximum standardised uptake value of positron emission tomography as a predictor of oesophageal cancer outcomes.
    Lai HH, Ho W, Lo CM, Chuang KH, Chen Y, Chen LC, Lu HI.
    J Cardiothorac Surg; 2024 Oct 01; 19(1):567. PubMed ID: 39354562
    [Abstract] [Full Text] [Related]

  • 6. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.
    Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.
    BMC Med Imaging; 2017 Jan 05; 17(1):1. PubMed ID: 28056868
    [Abstract] [Full Text] [Related]

  • 7. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
    Yuan H, Tong DK, Vardhanabhuti V, Law SY, Chiu KW, Khong PL.
    Nucl Med Commun; 2016 Sep 05; 37(9):947-55. PubMed ID: 27145438
    [Abstract] [Full Text] [Related]

  • 8. Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery.
    Chen YH, Lue KH, Chu SC, Chang BS, Wang LY, Liu DW, Liu SH, Chao YK, Chan SC.
    Ann Nucl Med; 2019 Sep 05; 33(9):657-670. PubMed ID: 31218571
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.
    Dis Esophagus; 2017 Aug 01; 30(8):1-10. PubMed ID: 28575243
    [Abstract] [Full Text] [Related]

  • 10. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D, Yoshida N, Watanabe M, Shiraishi S, Ishimoto T, Kosumi K, Tokunaga R, Taki K, Higashi T, Harada K, Miyata T, Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yamashita Y, Baba H.
    J Gastroenterol; 2016 Aug 01; 51(8):788-95. PubMed ID: 26671045
    [Abstract] [Full Text] [Related]

  • 11. Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Kim JY, Yun JK, Kim YH, Park SI, Lee JH, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Ahn JY, Kim SB, Cho KJ, Ryu JS, Kim JH, Kang J, Park SR, Kim HR.
    Ann Surg Oncol; 2024 Oct 01; 31(10):6662-6672. PubMed ID: 38954089
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of clinical and 18F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma.
    Marr L, Haller B, Pyka T, Peeken JC, Jesinghaus M, Scheidhauer K, Friess H, Combs SE, Münch S.
    Sci Rep; 2022 May 03; 12(1):7148. PubMed ID: 35504955
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
    Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Kemuriyama K, Sasaki Y, Imai K, Maeda E, Minamiya Y.
    Ann Surg Oncol; 2022 Feb 03; 29(2):1336-1346. PubMed ID: 34355333
    [Abstract] [Full Text] [Related]

  • 15. SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.
    Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y.
    World J Surg Oncol; 2021 Apr 09; 19(1):105. PubMed ID: 33836789
    [Abstract] [Full Text] [Related]

  • 16. Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus.
    Dewan A, Sharma SK, Dewan AK, Khurana R, Gupta M, Pahuja A, Srivastava H, Sinha R.
    J Gastrointest Cancer; 2017 Mar 09; 48(1):42-49. PubMed ID: 27604122
    [Abstract] [Full Text] [Related]

  • 17. Clinical Significance of 18F-Fluorodeoxyglucose-Positron Emission Tomography-Positive Lymph Nodes to Outcomes of Trimodal Therapy for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Aoki Y, Furukawa T, Okada M.
    Ann Surg Oncol; 2019 Jun 09; 26(6):1869-1878. PubMed ID: 30675704
    [Abstract] [Full Text] [Related]

  • 18. Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma.
    Huang YC, Li SH, Lu HI, Hsu CC, Wang YM, Lin WC, Chen CJ, Ho KW, Chiu NT.
    PLoS One; 2019 Jun 09; 14(1):e0210055. PubMed ID: 30615636
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS, Mook S, Verheij M, Mul VEM, Bergman JJ, Bartels-Rutten A, Ter Beek LC, Beets-Tan RGH, Bennink RJ, van Berge Henegouwen MI, Brosens LAA, Defize IL, van Dieren JM, Dijkstra H, van Hillegersberg R, Hulshof MC, van Laarhoven HWM, Lam MGEH, van Lier ALHMW, Muijs CT, Nagengast WB, Nederveen AJ, Noordzij W, Plukker JTM, van Rossum PSN, Ruurda JP, van Sandick JW, Weusten BLAM, Voncken FEM, Yakar D, Meijer GJ, PRIDE study group.
    BMC Cancer; 2018 Oct 20; 18(1):1006. PubMed ID: 30342494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.